FY2025 EPS Estimates for Arvinas Cut by Cantor Fitzgerald

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Equities researchers at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of Arvinas in a research note issued to investors on Thursday, August 7th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings per share of ($1.12) for the year, down from their prior estimate of ($0.56). The consensus estimate for Arvinas' current full-year earnings is ($3.81) per share. Cantor Fitzgerald also issued estimates for Arvinas' FY2026 earnings at ($1.64) EPS.

Several other brokerages have also commented on ARVN. HC Wainwright decreased their price objective on shares of Arvinas from $24.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. Truist Financial reaffirmed a "hold" rating and issued a $11.00 price objective (down from $21.00) on shares of Arvinas in a research report on Monday, May 5th. Wells Fargo & Company decreased their price objective on shares of Arvinas from $19.00 to $16.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. Piper Sandler reissued an "overweight" rating and set a $14.00 price target (down from $24.00) on shares of Arvinas in a research report on Friday, May 2nd. Finally, Citigroup reduced their price target on shares of Arvinas from $10.00 to $9.50 and set a "neutral" rating for the company in a research report on Monday, May 5th. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Arvinas has a consensus rating of "Moderate Buy" and a consensus target price of $19.76.

Arvinas Stock Up 0.7%

Shares of Arvinas stock traded up $0.05 during midday trading on Monday, hitting $7.13. The company had a trading volume of 242,566 shares, compared to its average volume of 2,181,819. The stock has a market cap of $523.48 million, a price-to-earnings ratio of -7.04 and a beta of 2.22. The company has a fifty day simple moving average of $7.51 and a 200 day simple moving average of $9.66. Arvinas has a 12-month low of $5.90 and a 12-month high of $29.61.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.03. The firm had revenue of $22.40 million during the quarter, compared to analyst estimates of $34.42 million. Arvinas had a negative net margin of 19.47% and a negative return on equity of 12.01%. Arvinas's revenue was down 70.7% on a year-over-year basis. During the same period last year, the firm posted ($0.49) EPS.

Institutional Investors Weigh In On Arvinas

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARVN. LPL Financial LLC increased its holdings in Arvinas by 12.5% in the 4th quarter. LPL Financial LLC now owns 18,669 shares of the company's stock worth $358,000 after acquiring an additional 2,077 shares in the last quarter. Bank of Montreal Can increased its holdings in Arvinas by 2.7% in the 4th quarter. Bank of Montreal Can now owns 39,407 shares of the company's stock worth $755,000 after acquiring an additional 1,044 shares in the last quarter. Invesco Ltd. increased its holdings in Arvinas by 1.6% in the 4th quarter. Invesco Ltd. now owns 37,254 shares of the company's stock worth $714,000 after acquiring an additional 581 shares in the last quarter. Kennedy Capital Management LLC increased its holdings in Arvinas by 42.0% in the 4th quarter. Kennedy Capital Management LLC now owns 208,992 shares of the company's stock worth $4,006,000 after acquiring an additional 61,802 shares in the last quarter. Finally, Barclays PLC increased its holdings in Arvinas by 43.8% in the 4th quarter. Barclays PLC now owns 175,019 shares of the company's stock worth $3,354,000 after acquiring an additional 53,320 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company's stock.

Insider Buying and Selling at Arvinas

In other news, CFO Andrew Saik sold 5,700 shares of Arvinas stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $7.61, for a total transaction of $43,377.00. Following the completion of the transaction, the chief financial officer directly owned 164,401 shares of the company's stock, valued at $1,251,091.61. The trade was a 3.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.73% of the stock is currently owned by company insiders.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.